Healthcare Services Group (HCSG) Q2 2025 earnings summary

Executive summary

• Q2 2025 revenue grew 7.6% year-over-year to $458.5 million, marking the fifth consecutive sequential increase and the highest growth rate since Q1 2018, driven by new client wins and high retention rates above 90%.

• Net loss was $32.4 million, or $0.44 per diluted share, primarily due to a $61.2 million non-cash charge from Genesis Healthcare's bankruptcy.

• Cash flow from operations was $28.8 million; adjusted for payroll accrual, it was $8.5 million, up $10.9 million year-over-year.

• Strategic priorities include management development, sales pipeline conversion, retention, cost management, and cash flow optimization.

• Announced a $50 million, 12-month share repurchase plan and raised 2025 cash flow forecast.

Financial highlights

• Q2 2025 revenue was $458.5 million, up from $426.3 million in Q2 2024; Environmental/Housekeeping and Dietary segments reported $205.8 million and $252.7 million, respectively.

• Net loss was $32.4 million, or $0.44 per diluted share, including a $0.65 per share non-cash charge ($61.2 million pre-tax) related to Genesis.

• Cash flow from operations was $28.8 million; adjusted for payroll accrual, it was $8.5 million.

• SG&A was $49.2 million reported, $44.5 million adjusted (9.7% of revenue).

• Cash and marketable securities at quarter end were $164.1 million; credit facility undrawn.

Outlook and guidance

• 2025 mid-single-digit revenue growth expectations reiterated, with Q3 revenue guidance of $455–$465 million.

• 2025 cash flow from operations forecast (excluding payroll accrual changes) raised to $70–$85 million from $60–$75 million.

• Cost of services targeted at 86% for the second half of 2025; SG&A expected in the 9.5%–10.5% range near term, with a long-term goal of 8.5%–9.5%.

• Capital expenditures for 2025 are estimated at $5M–$7M, with $3.1M spent through June 30, 2025.

• The company expects to maintain adequate liquidity and compliance with financial covenants for the next twelve months.